Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne
Dyne Therapeutics recently shared that the FDA issued a clinical hold on their Investigational New Drug (IND) application for the Phase I/II study of their exon skipping therapy utilizing a conjugated monoclonal antibody DYNE-251. For…Learn More